2023-05-03 02:56:35 ET
- Viracta Therapeutics ( NASDAQ: VIRX ) said on Tuesday that Chief Medical Officer, Lisa Rojkjaer, M.D., will be leaving the company to pursue another opportunity, effective May 5, 2023.
- Donald Strickland, M.D., Viracta’s Vice President, Clinical Development and Medical Director, and Yisrael Katz, M.D., Senior Medical Director, will continue to oversee Viracta’s pivotal NAVAL-1 trial and solid tumor clinical program, respectively.
- Shares of VIRX are up 3.25% after-hours on Tuesday.
For further details see:
Viracta Therapeutics CMO Lisa Rojkjaer, M.D to depart